MUMBAI, India, Jan. 2 -- Intellectual Property India has published a patent application (202541123204 A) filed by G Ashwin Prabhu; Ms. Joselin Reina J; Ms. Ferlinsa J; Ms. Theevika K; and Ms. Poornimaa Mu, Chennai, Tamil Nadu, on Dec. 6, 2025, for 'reverse docking study unravels the potential human targets of ectoine and auriculamide.'
Inventor(s) include Ms. Joselin Reina J; Ms. Ferlinsa J; Ms. Theevika K; and Ms. Poornimaa Mu.
The application for the patent was published on Jan. 2, under issue no. 01/2026.
According to the abstract released by the Intellectual Property India: "This invention presents an integrated computational approach for identifying the human targeting potential of two natural compounds, ectoine and auriculamide, obtained from the under explored bacterium Saccharopolyspora erythraea NRRL 2338. Although this strain is well known for erythromycin production, its secondary metabolites have not been studied in detail. Genome mining confirms the presence of a complete ectoine biosynthesis cluster and genetic signatures that support auriculamide production. ADMET analysis shows that both compounds have good absorption, low toxicity and safe pharmacokinetic behaviour. Reverse target prediction identifies eighty-five human protein targets for ectoine and two hundred ninety-nine targets for auriculamide. Many of these targets are involved in stress protection, immune balance, cell repair and tissue recovery. Reverse docking through CB Dock validates these findings, with ectoine showing stronger binding for twelve proteins and auriculamide showing stronger binding for two hundred sixty-four proteins compared to native ligands. These results present strong evidence that ectoine and auriculamide possess significant biological relevance. The invention establishes Saccharopolyspora erythraea NRRL 2338 as a valuable source of multifunctional natural compounds with potential applications in medicine, cosmetics and environmentally responsible technologies."
Disclaimer: Curated by HT Syndication.
